Skip to main content
Premium Trial:

Request an Annual Quote

Joe Keegan

Courtagen Life Sciences has appointed Joe Keegan to its board of directors. Keegan served as CEO of protein analysis products firm ForteBio, which was sold to Pall in 2012, and was CEO of Molecular Devices for nine years, prior to that firm's acquisition in 2007 by MDS for $615 million. He also previously served as president of worldwide tissue culture and VP, general manager of worldwide flow cytometry for Becton Dickinson, and VP of the microscopy and scientific instruments division of Leica.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.